Depression and Anxiety Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have agreed to participate in the "Biobanking" program at the Max Planck Institute of Psychiatry
- People aged 18 or older
- People who have been formally diagnosed with Major Depressive Disorder (a serious type of depression) confirmed by a structured interview
- People whose depression has not responded to at least one or two previous treatments (known as treatment-resistant depression, stage I or II)
- People for whom antidepressant medication has been recommended by their doctor
- People for whom a doctor has recommended adding lithium (a mood-stabilising medication) to their treatment
- People who are able to understand the study and give their written agreement to take part
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People under the age of 18
- People with certain health conditions that make taking lithium unsafe (confirm with trial site)
- People who have previously experienced a hypomanic or manic episode (periods of unusually high or elevated mood and energy)
- People taking two or more antidepressant medications at the same time as lithium, unless one of those medications is specifically used to help with sleep, such as Mirtazapine, Mianserin, or Trazodone
- People already using a different add-on medication strategy alongside lithium
- People taking more than 100 mg in total of Quetiapine (a psychiatric medication), in either its immediate- or extended-release form
- People currently experiencing a substance use disorder, except for moderate alcohol or benzodiazepine use related to the current episode of depression, or smoking
- People considered unsuitable for the study by the investigator for any reason
- People with significant conditions affecting the brain or nervous system, such as stroke, brain tumours, epilepsy (current or past), brain inflammation or autoimmune conditions affecting the brain, traumatic brain injury, or prior brain surgery
- People who are not able to give informed consent
- People who have received electroconvulsive therapy (ECT) during their current episode of depression
- People who have received repetitive transcranial magnetic stimulation (rTMS) during their current episode of depression
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Falkai, MD, Max-Planck-Institute of Psychiatry
Phone: 0049-89-30622-1418
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
multimodal and multivariate signature to predict outcome of lithium augmentation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.